The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease.

Permalink
https://escholarship.org/uc/item/2fk3w57b

Journal
The Journal of experimental medicine, 205(4)

ISSN
0022-1007

Authors
Carlson, Thaddeus
Kroenke, Mark
Rao, Praveen
et al.

Publication Date
2008-04-01

DOI
10.1084/jem.20072404

Peer reviewed
The Th17–ELR⁺ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease

Thaddeus Carlson,¹ Mark Kroenke,¹ Praveen Rao,¹ Thomas E. Lane,³ and Benjamin Segal¹,²

¹Department of Microbiology and Immunology and ²Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642
³Department of Molecular Biology and Biochemistry and Center for Immunology, University of California, Irvine, Irvine, CA 92697

The ELR⁺ CXC chemokines CXCL1 and CXCL2 are up-regulated in the central nervous system (CNS) during multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE). However, their functional significance and the pathways regulating their expression are largely unknown. We show that transfer of encephalitogenic CD4⁺ Th17 cells is sufficient to induce CXCL1 and CXCL2 transcription in the spinal cords of naive, syngeneic recipients. Blockade or genetic silencing of CXCR2, a major receptor for these chemokines in mice, abrogates blood–brain barrier (BBB) breakdown, CNS infiltration by leukocytes, and the development of clinical deficits during the presentation as well as relapses of EAE. Depletion of circulating polymorphonuclear leukocytes (PMN) had a similar therapeutic effect. Furthermore, injection of CXCR2⁺ PMN into CXCR2⁻/⁻ mice was sufficient to restore susceptibility to EAE. Our findings reveal that a Th17–ELR⁺ CXC chemokine pathway is critical for granulocyte mobilization, BBB compromise, and the clinical manifestation of autoimmune demyelination in myelin peptide–sensitized mice, and suggest new therapeutic targets for diseases such as MS.
maintenance of autoimmune demyelinating disease, in which infiltrates are dominated by lymphocytes and monocytes. Although PMN have been detected entering the CNS during the preclinical phase of EAE (17), their relative paucity in mature EAE and MS lesions has led some investigators to question their importance (8). With regard to more populous myeloid subsets in EAE and MS lesions, activated macrophages are recruited to the CNS by a CCL2-dependent pathway across several EAE models (18). Perhaps because of such observations, the role of ELR+ CXC chemokines in the pathophysiology of autoimmune demyelination has not been previously investigated in depth. However, a growing body of data indicates that they merit attention. For example, IL-17, a potent inducer of ELR+ CXC chemokines, was recently implicated in the pathogenesis of both EAE and MS (19–21). In addition, McColl et al. found that in vivo depletion of PMN prevents acute EAE induced either by active immunization or adoptive transfer (22). Interestingly, PMN comprise a significant percentage of CNS-infiltrating leukocytes in an atypical and severe form of EAE manifested by IFN-γ and IFN-γ receptor knockout mice, as well as in aggressive forms of human inflammatory demyelinating disease, such as Marburg’s variant of MS and hemorrhagic leukoencephalitis, suggesting that these cells might directly promote CNS inflammation and/or white matter injury (9, 23, 24). Collectively, these findings led us to comprehensively examine for the first time the role of CXCR2 and ELR+ CXC chemokines in conventional EAE models, to investigate the relationship between TH17 cell infiltration and ELR+ CXC chemokine expression in the CNS, and to specifically address whether PMN activation/recruitment via ELR+ CXC chemokine pathways is necessary for the development of relapses after clinical onset.

RESULTS

CNS expression of ELR+ CXC chemokines and CXCR2 mirrors clinical disease activity during relapsing–remitting EAE

To determine the pattern of ELR+ CXC chemokine expression throughout the course of relapsing–remitting disease, we immunized SJL mice with an immunodominant epitope of proteolipid protein (PLP139-151) in CFA and measured CNS expression of CXCL1 and CXCL2 mRNA in samples grouped according to clinical stage. In agreement with earlier reports (5–8), we found that CNS CXCL1 and CXCL2 were up-regulated from baseline levels (as measured in spinal cords from naive mice) at the peak of clinical EAE (Fig. 1 A). Expression of both chemokines fell to baseline during the subsequent remission and rebounded during relapse. Peptidoglycan recognition protein (PGRP), a PMN-specific marker (25), and CXCR2, an ELR+ CXC chemokine receptor expressed predominantly by PMN, exhibited similar kinetics. The same was true of the proinflammatory T cell effector cytokines IL-17 and IFN-γ and the ML chemokine CCL2. In contrast, CCL19 transcripts were elevated during the initial episode but progressively fell with each successive stage, whereas CCL3 and CCL5 transcripts were stable at a heightened level throughout the course. IL-10 was not elevated to a statistically significant extent at any stage. Expression of every chemokine and cytokine in our panel remained at baseline levels across multiple time points in spinal cords of mice immunized with an immunodominant epitope of influenza nucleoprotein (NP160-283).

As mentioned earlier, PMN have been detected crossing the blood–brain barrier (BBB) during the preclinical stage of EAE, when inflammatory infiltrates are beginning to form but before the manifestation of neurological deficits (17). Therefore, we measured CNS CXCL1 and CXCL2 on a daily basis starting on day 3 after immunization with PLP139-151. Transcripts encoding CXCL1 and CXCL2, as well as CXCR2 and PGRP, were detectable above baseline levels as early as 4 d before the expected day of clinical onset and increased progressively thereafter (Fig. 1 B). CD4, IL-17, and IFN-γ mRNA followed a similar pattern. In contrast, transcripts encoding CCL2, CCL3, CCL5, and CCL19 rose above baseline at later time points than the ELR+ CXC chemokines, suggesting that PMN may be actively recruited to the spinal cord before most other inflammatory cells. IL-10 was transcribed at a low level that did not change during the course of disease.

Transfer of purified myelin–reactive CD4+ Th17 cells is sufficient to induce CXCL1 and CXCL2 expression in the CNS

Th17 cells have recently been implicated in the pathogenesis of EAE and MS, as well as other organ-specific autoimmune diseases (19–21). IL-17 stimulates ELR+ CXC chemokine production in multiple cell types. Therefore we questioned whether transfer of myelin-specific CD4 Th17 cells would be sufficient to induce CXCL1 and CXCL2 transcription in the spinal cords of naive, syngeneic hosts. Purified CD4+ T cells, from donor SJL mice primed with PLP139-151 in IFA, were challenged with antigen for 96 h in the presence of recombinant IL-23, IL-12, or a neutralizing antibody against the IL-12/IL-23 p40 chain before injection into previously unmanipulated syngeneic hosts. PLP-reactive T cells proliferated in a similar fashion (Fig. 2 A, right) and expanded to a similar extent (based on yields of viable lymphoblasts; not depicted) under each set of culture conditions in vitro. As expected, IL-23–stimulated cells secreted large quantities of IL-17, whereas IL-12–stimulated cells secreted large quantities of IFN-γ during antigenic challenge in vitro (Fig. 2 A, left). Cells cultured with anti-p40 produced neither of those cytokines to detectable levels. IL-23–stimulated cells preferentially induced expression of IL-17 mRNA in spinal cords of adoptive transfer recipients (Fig. 2 B). In contrast, IL-12–stimulated cells induced CNS up-regulation of IFN-γ but not IL-17.

Spinal cords from mice injected with IL-23–driven Th17 cells expressed dramatically elevated levels of CXCL1 and CXCL2, as well as PGRP (a neutrophil-specific marker) and G-CSF, compared with cords from naive mice (Fig. 2 B and not depicted). In contrast, those molecules remained at background levels in spinal cords from mice injected with PLP-reactive CD4+ T cells that had been reactivated in the
presence of anti-IL-12 p40. By comparison to the Th17 effectors, IL-12-driven Th1 cells were relatively inefficient at inducing ELR+ CXC chemokines in the CNS. Of note, PLP-specific donor T cells from each set of cultures survived/expanded to a comparable extent in the peripheral lymphoid organs of host mice, as assessed by lymphoproliferative recall responses on day 14 after transfer (unpublished data). Splenocytes harvested from recipients of IL-23-polarized cells secreted IL-17 and splenocytes from recipients of IL-12-polarized cells secreted IFN-γ in an antigen-specific manner, suggesting that the donor cells maintained their Th phenotypes after adoptive transfer (unpublished data).

**CXCR2 blockade abrogates EAE**

To assess the physiological significance of ELR+ CXC chemokine expression in our model, we injected SJL mice with either anti-CXCR2 antiserum or normal rabbit serum (NRS) between days 8 and 12 after immunization with PLP139-151 or NP260-283 for analysis by real-time RT-PCR (n = 5 mice per group). *P < 0.05 for PLP-immunized mice compared with NP-immunized mice. n.s., not significantly different from naive spinal cords.

**Figure 1.** ELR+ CXC chemokines are up-regulated in the CNS during preclinical and active stages of EAE. (A) SJL mice were immunized with PLP139-151 or NP260-283 (control) in CFA. Spinal cord RNA was isolated from PLP139-151-primed mice during distinct stages of EAE, or from NP260-283-primed mice at analogous time points after immunization, for real-time RT-PCR analysis. Data represent fold induction compared with naive spinal cords (n = 4 mice per group). (B) RNA was extracted from spinal cords between days 8 and 12 after immunization with PLP139-151 or NP260-283 for analysis by real-time RT-PCR (n = 5 mice per group). *P < 0.05 for PLP-immunized mice compared with NP-immunized mice. n.s., not significantly different from naive spinal cords.
Collectively these data suggest that the therapeutic effect of anti-CXCR2 may be secondary to blockade of PMN mobilization from the bone marrow into the bloodstream.

Experiments using CXCR2−/− (26) mice corroborated our findings with the CXCR2-neutralizing antiserum. In repeated experiments, 90–100% of myelin antigen–primed WT mice developed EAE (mean clinical score = 2–3), signifying conspicuous hind-limb paresis (Fig. 3 G). In contrast, none of the CXCR2−/− mice on the same genetic background that were subjected to the same immunization protocol acquired neurological deficits. CXCR2+/− mice exhibited an intermediate phenotype.

PMN are mobilized from the bone marrow and accumulate in the CNS during preclinical and acute stages of EAE.

To monitor the migration of PMN during the development of EAE, we tracked Ly6G+, 7/4+, MHC class II− cells in the circulatory and CNS compartments by flow cytometry. PMN began accumulating in the blood during the preclinical phase, and their percentage among circulating leukocytes rose through peak disease (Fig. 4, A and B). Similarly, PMN appeared in the CNS shortly before the expected day of clinical onset, and their absolute numbers increased in proportion to the growing inflammatory infiltrate (Fig. 4, C and D).
However, 2–3 d after the cessation of injections, in agreement with recovery of the circulating PMN pool, we consistently observed an acute increase in cerebrovascular permeability and the onset of hind-limb weakness. Furthermore, initiation of RB6 treatments during remission prevented subsequent cerebrovascular compromise and clinical relapse (Fig. 5, D and E). Histological studies corroborated our clinical findings, demonstrating that RB6 treatment completely inhibited CNS inflammation in PLP-immunized mice (Fig. 5, F and G). Therefore, PMN depletion by RB6 had similar effects to ELR+ CXC chemokine blockade by anti-CXCR2 in maintaining the integrity of the BBB and preventing the clinical and histological manifestations of EAE.

PMN depletion does not alter peripheral myelin-specific T cell responses
PMN can directly trigger dendritic cell maturation via interactions between Mac-1 and DC-SIGN, thereby boosting
T cell proliferation and Th1 polarization (28). PMN also secrete cytokines and chemokines that can directly modulate T cell differentiation (29, 30). Therefore we investigated the effects of PMN depletion on the priming of myelin-specific T cells in the periphery. CD4+ T cells purified from the lymph nodes of PLP-immunized mice that had been injected either with RB6 or control antibodies mounted comparable lymphoproliferative and cytokine recall responses (Fig. 6, A and B). In contrast, RB6-treated mice failed to up-regulate IL-17, IFN-γ, or IL-6 in the CNS to the levels expressed in control mice at peak disease (Fig. 6 C). RB6 treatment also blocked CNS expression of PGRP, indicating that there was no detectable infiltration by PMN. Hence, reminiscent of our findings with the anti-CXCR2 antiserum, the therapeutic actions of RB6 are mediated during the effector stage, at a point after the generation of encephalitogenic CD4+ T cells in secondary lymphoid organs, and correlate with inhibition of PMN trafficking to the CNS.

**Resistance of CXCR2−/− mice is overcome by transfer of CXCR2+/+ PMN**

Although ELR+ CXC chemokines are most widely characterized as attractants and activators of PMN, they can also mediate monocyte arrest (16). To determine whether CXCR2 expression on PMN is sufficient for EAE susceptibility, we injected CXCR2−/− mice with purified WT PMN over several days after immunization with PLP peptide. 100% of CXCR2−/− mice treated in this manner succumbed to clinical and histological EAE, although at a lower severity in comparison to...
ARTICLE

development of EAE. This is an unexpected finding in light of the current dogma regarding the immunopathogenesis of autoimmune demyelinating disease. Researchers studying EAE and other organ-specific autoimmune diseases have focused on the autoreactive T and/or B cells that guide pathological inflammation. Macrophages and, more recently, dendritic cells, have also received attention because of their role in presenting myelin antigens and in inflicting damage to the target organ (1, 31). Consequently, research involving chemokines in EAE has focused on the ELR+ CXC chemokines that serve as the main chemoattractants for monocytes and lymphocytes (3, 4).

Although PMN are among the first leukocytes to infiltrate the CNS in some models of EAE (17), they are scarce in mature infiltrates. Hence, PMN have not generally been posited as key effector cells in popular theories on the pathogenesis of EAE or relapsing-remitting MS. Nonetheless, previous

PLP-immunized WT mice (Fig. 7 and Table I). CXCR2−/− mice injected with WT macrophages according to the same schedule remained resistant to EAE induction. PMN transfer induced BBB breakdown and CNS expression of IFN-γ and IL-6 in primed CXCR2−/− hosts, whereas macrophage transfer failed to do so (Fig. 8, A and B; and not depicted). Importantly, transfer of WT PMN resulted in CNS expression of PGRP and CXCR2, demonstrating that donor PMN homed to the target organ during the inflammatory process. Antigen-specific proliferation and cytokine secretion of lymph node CD4+ T cells was comparable between PLP-primed WT and CXCR2−/− mice, as well as CXCR2−/− mice that received WT PMN transfers (Fig. 8, C and D).

DISCUSSION

The current study demonstrates that ELR+ CXC chemokines and CXCR2-expressing PMN are required for the development of EAE. This is an unexpected finding in light of the current dogma regarding the immunopathogenesis of autoimmune demyelinating disease. Researchers studying EAE and other organ-specific autoimmune diseases have focused on the autoreactive T and/or B cells that guide pathological inflammation. Macrophages and, more recently, dendritic cells, have also received attention because of their role in presenting myelin antigens and in inflicting damage to the target organ (1, 31). Consequently, research involving chemokines in EAE has focused on the ML and ELR− CXC chemokines that serve as the main chemoattractants for monocytes and lymphocytes (3, 4).

Figure 5. PMN depletion prevents BBB disruption and clinical and histopathological manifestations of EAE. SJL mice were injected with either RB6 or control IgG (0.5 mg per dose) every other day from days 8–16 (A–C, F, and G) or days 21–27 (D and E) after immunization with PLP139-151 in CFA. (A) PBLs were collected at serial time points and analyzed by flow cytometry. PMN were identified as CD11b+, 7/4+, MHC class II− cells. The percentage of PMN was averaged over six mice per group. A representative FACS profile of each group is shown. Data represent mean ± SD. (B) Daily clinical scores were averaged over six mice in each group. (C) BBB integrity was assessed during the indicated stages of EAE in the control IgG-treated group by Evans blue dye extravasation. Data represent mean ± SD of six mice per group. *, P < 0.05 compared with naive mice. (D) The mean daily clinical score of each group (n = 8) is shown. (E) BBB integrity was assessed during the time of relapse in the control IgG-treated group. Data represent mean ± SD of six mice per group. *, P < 0.05 compared with naive mice. (F and G) Spinal cords were harvested and fixed on day 14 after immunization with PLP139-151. Sections were Giemsa stained to visualize cell morphology. Images are representative of sections from four mice per group. All experiments were repeated three or more times with consistent results. Bars: (F, left; and G) 200 μm; (F, right) 50 μm.
animal models of neuroinflammation (10, 34). Conversely, administration of recombinant G-CSF was associated with acute relapses when given to MS patients undergoing bone marrow transplantation (35). Most strikingly, PMN depletion was recently reported to attenuate EAE induced either by active immunization or adoptive transfer (22). These observations are consistent with the results of our current study, which indicate that PMN-mobilizing and -activating factors play a critical role in facilitating autoimmune-mediated neuroinflammation and demyelination.

The mechanism of action of PMN in EAE remains to be elucidated. PMN produce chemokines and cytokines and participate in cell-to-cell interactions with dendritic cells that could modulate the differentiation and/or activation of lymphocytes and monocytes (28–30). However, our data indicate that PMN exert their functions during the effector rather than the induction phase of EAE because myelin-specific T cell expansion and Th1/Th17 differentiation were not impaired in either RB6-treated or CXCR2-deficient mice (Fig. 6, A and B; and Fig. 8, C and D). Furthermore, mice that were protected from EAE, either by anti-CXCR2 injection or PMN depletion, experienced exacerbations within days of treatment withdrawal (Fig. 3 A and Fig. 5 B). This indicates that encephalitogenic T cells had been generated in the periphery and were able to mediate disease as soon as functional PMN were available for collaboration. We and others (22) have found that PMN depletion suppresses EAE induced by the transfer of ordinarily encephalitogenic myelin-specific T cells (unpublished data). The ability of PMN to facilitate the trafficking and/or effector functions of memory T cells is not confined to autoimmune disease. Hence, CXCL1-dependent recruitment of PMN to cutaneous antigen challenge sites is required for the elicitation of contact hypersensitivity by previously primed, hapten-specific CD4+ and CD8+ T cells (36).

We postulate that PMN mediate or augment BBB breakdown during the period between the reactivation of myelin-specific T cells in the CNS and the massive influx of nonspecific leukocytes that heralds the onset of clinical EAE. In support of our hypothesis, PMN were recently shown to be important for increased vascular permeability and clinical disease in the K/BxN serum transfer model of arthritis (37). Furthermore, increased cerebrovascular permeability occurs in association with PMN infiltration of the CNS provoked by viral encephalitis, intracerebral injection of IL-1β or CXCL2, or by transgenic expression of CXCL1 in oligodendrocytes (38–42). In the case of the viral encephalitis and IL-1β injection models, depletion of PMN or neutralization of CXCL1 prevented compromise of the cerebrovasculature. Activated PMN can disrupt adherens junctions between endothelial cells via contact (β2 integrin)-dependent pathways and via secretion of factors that trigger endothelial cell contraction (azurocidin and hydrogen peroxide), up-regulation of adhesion molecules (TNF and glutamate), and extracellular matrix degradation (elastase and other proteases) (43–47). In addition, the culture of activated PMN with brain endothelial

Figure 6. PLP-specific peripheral CD4+ responses are not altered by PMN depletion, but CNS up-regulation of inflammatory markers is blocked. (A and B) CD4+ T cells were isolated from draining lymph nodes of PLP-immunized SJL mice that had been treated with either control IgG (closed bars and squares) or RB6 (open bars and circles). The purified T cells were cultured with naïve T cell–depleted splenocytes with or without 25 μg/ml PLP139-151, for EUSPOT (A) and [3H]thymidine uptake proliferation (B) assays. The EUSPOT data shown were generated by subtracting background spots (10 or fewer) that appeared in the absence of antigenic challenge. Data represent mean ± SD. (C) Spinal cords from PLP-immunized mice that had been treated with either control IgG or RB6 were analyzed by real-time RT-PCR. Data represent fold induction relative to naïve spinal cords (n = 5 mice per group). * P < 0.05 for IgG–compared with RB6-treated mice.

publications have demonstrated that ELR+ CXC chemokines, as well as other PMN-related factors such as leukotrienes and G-CSF, are up-regulated in the CNS during EAE and MS (6–8, 32, 33). CXCL8 was found to be elevated in the sera and peripheral blood mononuclear cells from MS patients in comparison to healthy volunteers (10). Furthermore, recombinant IFN-β, used in the clinical setting to suppress MS relapses, reduces CXCL8 expression in MS and inhibits both PMN infiltration of the CNS and BBB breakdown in
function require cell-to-cell adherence but not transendothelial migration (50). This observation suggests that adhesion of PMN to the cerebrovascular wall alone might be sufficient to increase its permeability in vivo. If so, the seemingly paradoxical proposition that PMN are mechanistically involved in EAE despite composing a minor percentage of CNS-infiltrating cells would be reconciled.

Resistance of CXCR2\(^{-/-}\) mice to EAE is reversed by the transfer of WT PMN (Table I, Fig. 7, and Fig. 8), indicating that ELR\(^+\) CXC chemokines drive PMN-dependent events that are crucial for the development of clinical disease. The fact that CXCR2\(^{-/-}\) mice supplemented with WT PMN experienced milder disease than WT littermates raises the possibility that expression of CXCR2 on cells other than PMN might also be important in this model of EAE. Nonetheless, our observation that PMN depletion and CXCR2 blockade have virtually identical effects on the clinical and histopathological features of EAE indicate that the ELR\(^+\) CXC chemokine pathway induces the activation and/or migration of PMN in a nonredundant fashion. These results contrast with those of Abromson-Leeman et al., who reported that three out of four myelin-specific T cell lines successfully transferred EAE to naive CXCR2\(^{-/-}\) mice (51). However, it is not clear that in vitro–derived T cell lines mimic the biological properties of endogenous pools of myelin-specific T cells activated in vivo.

Table I. WT PMN transfer restores EAE susceptibility in CXCR2\(^{-/-}\) mice

| Incidence | Mean day of onset | Mean peak score |
|-----------|------------------|-----------------|
| WT        | 100%             | 12.2            | 2.2             |
| \(-/-\)   | 0%               | –               | 0               |
| WT PMN→\(-/-\) | 100% | 13.5            | 1               |
| WT BMMac→\(-/-\) | 0% | –               | 0               |

Data are representative of at least three independent experiments. WT, \(n = 15\); \(-/-\), \(n = 12\); WT PMN→\(-/-\), \(n = 10\); WT BMMac→\(-/-\), \(n = 9\).

\(5 \times 10^6\) cells transferred i.p. daily from day 10–14 after immunization.

**Figure 7.** WT PMN promote neuroinflammation in myelin-immunized CXCR2\(^{-/-}\) mice. BALB/c CXCR2\(^{-/-}\) and CXCR2\(^{-/-}\) mice were immunized with PLP\(_{185-206}\) in CFA. CXCR2\(^{-/-}\) mice were injected with \(5 \times 10^6\) purified bone marrow PMN or BMMac daily between days 10 and 14 after immunization. Spinal cords were removed between days 13 and 15 after immunization, fixed, and hematoxylin and eosin stained. Representative sections of three mice per group are shown. Bars: (left and middle) 200 \(\mu\)m; (right) 50 \(\mu\)m.
(Fig. 1), raising the possibility that IL-17 amplifies ELR+ CXC chemokine production in EAE lesions as disease progresses. In fact, we have found that adoptive transfer of purified myelin-specific Th17, but not lineage-uncommitted, CD4+ T cells triggers conspicuous CXCL1 and CXCL2 transcription in the CNS (Fig. 2 B). On the other hand, EAE induction by myelin-reactive Th1 cells is more closely associated with CNS up-regulation of ELR+/H11002 than ELR+ CXC chemokines (unpublished data).

Furthermore, recipients of the T cell lines were irradiated before adoptive transfer. If our theory is correct, Abromson-Leemans’s protocol may have circumvented the requirement for PMN and ELR+ CXC chemokines because irradiation, in and of itself, could trigger both immediate and long-term BBB disruption (52).

The results of our experiments dovetail nicely with reports from other laboratories that the IL-23 – IL-17 axis plays a nonredundant role in the pathogenesis of EAE (53). Although Th17 cells have emerged as critical autoimmune effectors, the events linking IL-17 signaling to target organ inflammation and tissue damage are unknown. A major function of IL-17 is to induce production of ELR+ CXC chemokines (54). CNS expression of ELR+ CXC chemokines closely mirrors that of IL-17 during the relapsing-remitting course of EAE
that block PMN activation and/or adherence to the luminal surface of CNS vessels might be therapeutically effective without having to cross the BBB.

MATERIALS AND METHODS

Mice. SJL and BALB/c mice were purchased from the National Cancer Institute at 6–8 wk of age. BALB/c CXCR2−/−, CXCR2−/+ , and CXCR2+/+ mice littermates (originally purchased from Jackson ImmunoResearch Laboratories) were bred in our laboratory, as previously described (26). Mice were housed in a specific pathogen-free facility at the University of Rochester School of Medicine and Dentistry. All experiments were approved by the University of Rochester Committee on Animal Resources.

Antibodies and reagents. The following mAbs were purchased for flow cytometry: B220 (RA3-62), CD3 (145-2C11), CD4 (RM4-5), CD8 (53-6.7), CD11c (HL3), Ly6C (AL-21), Ly6G (1A8), MHC class II (7-16.17; BD Biosciences); 7/4 (Caltag and Serotec); and CD11b (M1/70), F4/80 (BM8), Gr-1 (RB6), and M-CSF R (AFS98; eBioscience). RB6 (Gr-1) mAbs were purified from hybridoma supernatants on protein G columns (GE-BD Biosciences); 7/4 (Caltag and Serotec); and CD11b (M1/70), F4/80 (BM8), Gr-1 (RB6), and M-CSF R (AFS98; eBioscience). RB6 (Gr-1) mAbs were purified from hybridoma supernatants on protein G columns (GE Healthcare). Recombinant mouse M-CSF was purchased from PeproTech.

Induction and assessment of EAE. Mice were immunized subcutaneously over the flanks with 100 μg PLP139-151 (SJL) or PLP185-206 (BALB/c) in CFA containing 250 μg Mycobacterium tuberculosis H37RA (Difco). BALB/c mice were injected i.p. with 300 ng Bovine pertussis toxin (List Biological Laboratories) on days 0 and 2 after immunization. Clinical assessment of EAE was performed according to the following criteria: 0, no disease; 1, limp tail; 2, hind-limb weakness; 3, partial hind-limb paralysis; 4, complete paralysis of one or more limbs; and 5, moribund state.

CXCR2 neutralization. Anti-CXCR2 antiserum was prepared by immunizing rabbits with a peptide (Met-Gly-Glu-Phe-Lys-Val-Asp-Lys-Phe-Asn-Ile-Glu-Glu-Phe-Phe-Ser-Gly) derived from the ligand binding site of CXCR2 (Biosynthesis) (13). To block CXCR2 in vivo, 0.5 ml of anti-CXCR2 antiserum was injected i.p. every third day. NRS was used as a control. Anti-CXCR2 antiserum failed to induce complement-mediated lysis of purified PMN in vitro or to deplete PMN (Ly6G+, 7/4+, MHC class II− cells) after in vivo administration of 0.5 ml i.p.; every third day (unpublished data). The antiserum stained WT but not CXCR2−/− PMN (unpublished data).

Flow cytometric analysis. Cells were incubated with FcBlock (hybridoma 2.4G2; American Type Culture Collection) followed by biotinylated or fluorescent-conjugated antibodies for 10 min on ice. For secondary staining, cells were washed and incubated with PerCP- or allophycocyanin-conjugated streptavidin for an additional 10 min. Data acquisition was performed on a flow cytometer (FACSCalibur; BD Biosciences) and analyzed with FlowJo software (Tree Star, Inc.).

Histology. Mice were perfused with 10% formalin, and vertebral columns were dissected and decalcified with Immunocal (Decal Chemical Corporation). Cords were fixed in 10% formalin, paraffin embedded, sectioned, and Giemsa stained. Images were captured on a microscope (Axioplan 2; Carl Zeiss, Inc.) with a SPOT camera and SPOT Advanced software (Diagnostic Instruments, Inc.).

CNS cell isolation. Mice were anesthetized with avertin and perfused with PBS by the intracardiac route 2 h later. Spinal cord and kidney samples were homogenized in formamide (20 ml/g of tissue wet weight; Sigma-Aldrich), and dye was extracted overnight. After centrifugation at 21,000 g for 30 min, supernatants were removed and absorbance was measured at 620 and 740 nm. Background absorbance (calculated as −log OD620 = (0.964)(−log OD740) − 0.0357) was subtracted to obtain the data shown in the figures, as previously described (55). Relative permeability represents the ratio of Evans blue extravasation (micrograms of dye per gram of tissue) from spinal cord homogenates to kidney homogenates.

Real-time RT-PCR. RNA was isolated with TRIzol (Invitrogen) according to the manufacturer’s protocol. cDNA was synthesized with a reverse transcription kit (QuantiTect; QIAGEN). PCR was performed using a single-color real-time PCR detection system (Mysq; Bio-Rad Laboratories). Primers and probes were designed with Beacon Designer (Premier Biosoft International). Samples were amplified over 40 cycles according to the following protocol: 15 s at 95°C, 1 min at 60°C. Target gene expression was normalized to GAPDH. The relative expression of mRNA in tissues from immunized mice versus naive mice was determined using the REST-XL software tool (version 2) (56), and data are represented as fold induction compared with naive controls. General trends and statistical significance were similar when β-actin was used as the housekeeping gene (unpublished data).

Cell transfer experiments. PMN (>97% purity) were isolated from bone marrow using anti-Ly6G-biotin and antibiotin microbeads (Miltenyi Biotec). Enriched bone marrow macrophages (BMMac; 82–87% purity) were enriched from whole bone marrow cells by culture with 10 ng/ml M-CSF. After 5 d, adherent cells were harvested and isolated over a 62% Percoll gradient by centrifugation for 30 min at 1,500 g. Ly6G+ cells were removed with anti-Ly6G-biotin/antibiotin beads. Cytospins and flow cytometry were used to confirm cellular purity (Fig. S2, available at http://www.jem.org/cgi/content/full/jem.20072404/DC1). Recipient mice were injected with 5 × 10^6 PMN or BMMac i.p.

Statistical analysis. Real-time RT-PCR data were analyzed by the pairwise fixed reallocation randomization test with REST-XL software (version 2). All other data were analyzed by the Mann-Whitney test with Prism 5 software (GraphPad Software).

Online supplemental material. Fig. S1 shows the PMN depletion efficiency and specificity of the RB6 mAb on PBL subsets. Fig. S2 shows the purity of PMN and BMMac used for transfer into CXCR2−/− mice. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20072404/DC1.
REFERENCES

1. Fischer, H.G., and G. Reichmann. 2001. Brain dendritic cells and mononuclear cells in the nervous system: heaven (or hell) is in the details. Curr. Opin. Immunol. 13:683–689.

2. Godiska, R., D. Chantry, G.N. Dietsch, and P.W. Gray. 1995. The CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. Am. J. Pathol. 168:1389–1395.

3. Huang, D.R., J. Wang, P. Kviskak, B.J. Rollins, and R.M. Ranosfho. 2001. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J. Exp. Med. 193:713–726.

4. Komiyama, Y., S. Nakae, T. Matsuki, A. Nambu, H. Ishigame, S. Kakuta, K. Sudo, and Y. Iwakura. 2006. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 177:566–573.

5. Takakura, M. Minohara, H. Murai, F. Mihara, T. Taniwaki, and J. Takakura. 2001. CXC chemokine receptor expression. J. Neuroimmunol. 110:195–208.

6. Glabinski, A.R., M. Tani, R.M. Strieuter, V.K. Tuohey, and R.M. Ranosfho. 1997. Synchronous synthesis of alpha- and beta-chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis. Am. J. Pathol. 150:617–630.

7. Glabinski, A.R., V.K. Tuohey, and R.M. Ranosfho. 1998. Expression of chemokines RANTES, MIP-1alpha and GRO-alpha correlates with inflammation in acute experimental autoimmune encephalomyelitis. Neuroimmunomodulation. 5:166–171.

8. Godiska, R., D. Chantry, G.N. Dietzch, and P.W. Gray. 1995. Chemokine expression in murine experimental allergic encephalomyelitis. J. Neuroimmunol. 58:167–176.

9. Ishizu, T., M. Osoegawa, F.J. Met, H. Kikuchi, M. Tanaka, Y. Takakura, M. Minohara, H. Murai, F. Mihara, T. Taniwaki, and J. Kira. 2000. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain. 128:988–1000.

10. Lund, B.T., N. Ashikian, H.Q. Ta, Y. Chakryan, K. Manoukian, S. Groshen, W. Gilmore, G.S. Cheema, W. Stohl, M.E. Burnett, et al. 2004. Increased CXCL8/IL-8 expression in Multiple Sclerosis. J. Neuroimmunol. 153:161–171.

11. Del Rio, L., S. Bennouna, J. Salinas, and E.Y. Denkers. 2001. CXCR2 deficiency confers impaired neutrophil recruitment and increased susceptibility during Toxoplasma gondii infection. J. Immunol. 167:6503–6509.

12. Kielen, T., B. Barry, and W.F. Hickey. 2001. CXC chemokine receptor-2 ligands are required for neutrophil-mediated host defense in experimental brain abscesses. J. Immunol. 166:4634–4643.

13. Mehrad, B., R.M. Strieuter, T.A. Moore, W.C. Tsai, S.A. Lira, and T.J. Standiford. 1999. CXCR2 chemokine receptor-2 ligands are necessary components of neutrophil-mediated host defense in invasive pulmonary aspergillosis. J. Immunol. 163:6086–6094.

14. Podolyn, P.L., B.J. Bolognese, J.J. Foley, D.B. Schmidt, P.T. Buckley, K.L. Widdowson, Q. Jin, J.R. White, J.M. Lee, R.B. Goodman, et al. 2002. A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit. J. Immunol. 169:6435–6444.

15. Takaoka, A., Y. Tanaka, T. Tsuji, T. Jinushi, A. Hoshino, Y. Asakura, Y. Mitu, K. Watanabe, S. Nakake, Y. Togushi, et al. 2001. A critical role for mouse CXC chemokine (s) in pulmonary neutrophilia during Th type 1-dependent airway inflammation. J. Immunol. 167:2349–2353.

16. Boswert, W.A., D.M. Rose, K.A. Johnson, M.E. Fuentes, S.A. Lira, L.K. Curtis, and R.A. Terkelstalb. 2006. Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. Am. J. Pathol. 168:1389–1395.

17. Brown, A., D.E. McFarlin, and C.S. Rain. 1982. Chronologic neuropathology of relapsing experimental allergic encephalomyelitis in the mouse. Lab. Invest. 46:171–185.

18. Park, H., Z. Li, X.O. Yang, S.H. Chang, R. Nurieva, Y.H. Wang, Y. Wang, L. Hood, Z. Zhu, Q. Tian, and C. Dong. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6:1133–1141.

19. McColl, S.R., M.A. Staykova, A. Wozniak, S. Fordham, J. Bruce, and D.O. Willenborg. 1998. Treatment with anti-granulocyte antibodies inhibits the effector phase of experimental autoimmune encephalomyelitis. J. Immunol. 161:6421–6426.

20. Luchinetti, C.F., R.N. Mandler, D. McGavern, W. Bruck, G. Gleich, R.M. Ranosfho, C. Trebst, B. Weimenderker, D. Wingerchut, J.E. Parisi, and H. Lasnmann. 2002. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain. 125:1450–1461.

21. Tran, E.H., E.N. Prince, and T. Owens. 2000. IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines. J. Immunol. 164:2759–2768.

22. Liu, C., D. Gelius, G. Liu, H. Steiner, and R. DiZianski. 2000. Mammalian peptidoglycan recognition protein binds peptidoglycan with high affinity, is expressed in neutrophils, and inhibits bacterial growth. J. Biol. Chem. 275:24490–24499.

23. Cascallo, G., J.Lee, K. Kikk, A.M. Ryan, S. Pitts-Meek, B. Hultgren, W.I. Wood, and M.W. Moore. 1994. Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. Science. 265:682–684.

24. Conlan, J.W., and R.J. North. 1994. Neutrophils are essential for early anti-Listeria defense in the liver, but not in the spleen or peritoneal cavity, as revealed by a granulocyte-depleting monoclonal antibody. J. Exp. Med. 179:259–268.

25. van Gisbergen, K.P., M. Sanchez-Hernandez, T.B. Geijtenbeek, and Y. van Kooyk. 2005. Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN. J. Exp. Med. 201:1281–1292.

26. Bennouna, S., S.K. Bliss, T.J. Curiel, and E.Y. Denkers. 2003. Cross-talk in the innate immune system: neutrophils instruct recruitment and activation of dendritic cells during microbial infection. J. Immunol. 171:6052–6058.

27. Scapini, P., J.A. Lapinetti-Vera, S. Gasperini, F. Calzetti, F. Buzzoni, and M.A. Casetella. 2000. The neutrophil as a cellular source of chemokines. Inflammation. Rev. 17:195–203.

28. Tran, E.H., K. Hockstra, N. van Rooijen, C.D. Dijkstra, and T. Owens. 1998. Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice. J. Immunol. 161:3767–3775.

29. Conlon, C., G. Hermans, R. Pedotti, A. Brendolan, E. Schadt, H. Garren, and M.A. Cassetta. 2000. The neutrophil as a cellular source of chemokines. Inflamm. Rev. 17:195–203.

30. Whitney, L.W., S.K. Ludwin, H.F. McFarland, and W.E. Biddon. 2001. Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions. J. Neuroimmunol. 121:40–48.
ARTICLE

34. Veldhuis, W.B., S. Floris, P.H. van der Meide, L.M. Vos, H.E. de Vries, C.D. Dijkstra, P.R. Bar, and K. Nicolay. 2003. Interferon-beta prevents cytokine-induced neutrophil infiltration and attenuates blood-brain barrier disruption. J. Cereb. Blood Flow Metab. 23:1060–1069.

35. Openshaw, H., O. Stuve, J.P. Antel, R. Nash, B.T. Lund, L.P. Lund, V.H. Perry, and J.K. Hamilton, and R.L. Fairchild. 1999. GRO-alpha-mediated recruitment of neutrophils is required for elicitation of contact hypersensitivity. Eur. J. Immunol. 29:3485–3495.

36. Hamilton, and R.L. Fairchild. 1999. GROalpha-mediated recruitment of neutrophils is required for elicitation of contact hypersensitivity. Eur. J. Immunol. 29:3485–3495.

37. Pestka, S. 1994. Inhibitory effects of cytokines on neutrophil infiltration and angiogenesis. Immunol. Today 15:25–29.

38. Armao, D., M. Kornfeld, E.Y. Estrada, M. Grossetete, and G.A. Loscalzo. 2000. Tumor necrosis factor-alpha and interleukin-1beta mediate neutrophil infiltration of the injured brain. J. Neurosci. Methods 92:193–204.

39. Armao, D., M. Kornfeld, E.Y. Estrada, M. Grossetete, and G.A. Loscalzo. 2000. Tumor necrosis factor-alpha and interleukin-1beta mediate neutrophil infiltration of the injured brain. J. Neurosci. Methods 92:193–204.

40. Armao, D., M. Kornfeld, E.Y. Estrada, M. Grossetete, and G.A. Loscalzo. 2000. Tumor necrosis factor-alpha and interleukin-1beta mediate neutrophil infiltration of the injured brain. J. Neurosci. Methods 92:193–204.

41. Armao, D., M. Kornfeld, E.Y. Estrada, M. Grossetete, and G.A. Loscalzo. 2000. Tumor necrosis factor-alpha and interleukin-1beta mediate neutrophil infiltration of the injured brain. J. Neurosci. Methods 92:193–204.

42. Armao, D., M. Kornfeld, E.Y. Estrada, M. Grossetete, and G.A. Loscalzo. 2000. Tumor necrosis factor-alpha and interleukin-1beta mediate neutrophil infiltration of the injured brain. J. Neurosci. Methods 92:193–204.

43. Armao, D., M. Kornfeld, E.Y. Estrada, M. Grossetete, and G.A. Loscalzo. 2000. Tumor necrosis factor-alpha and interleukin-1beta mediate neutrophil infiltration of the injured brain. J. Neurosci. Methods 92:193–204.

44. Armao, D., M. Kornfeld, E.Y. Estrada, M. Grossetete, and G.A. Loscalzo. 2000. Tumor necrosis factor-alpha and interleukin-1beta mediate neutrophil infiltration of the injured brain. J. Neurosci. Methods 92:193–204.

45. Armao, D., M. Kornfeld, E.Y. Estrada, M. Grossetete, and G.A. Loscalzo. 2000. Tumor necrosis factor-alpha and interleukin-1beta mediate neutrophil infiltration of the injured brain. J. Neurosci. Methods 92:193–204.

46. Armao, D., M. Kornfeld, E.Y. Estrada, M. Grossetete, and G.A. Loscalzo. 2000. Tumor necrosis factor-alpha and interleukin-1beta mediate neutrophil infiltration of the injured brain. J. Neurosci. Methods 92:193–204.

47. Armao, D., M. Kornfeld, E.Y. Estrada, M. Grossetete, and G.A. Loscalzo. 2000. Tumor necrosis factor-alpha and interleukin-1beta mediate neutrophil infiltration of the injured brain. J. Neurosci. Methods 92:193–204.

48. Armao, D., M. Kornfeld, E.Y. Estrada, M. Grossetete, and G.A. Loscalzo. 2000. Tumor necrosis factor-alpha and interleukin-1beta mediate neutrophil infiltration of the injured brain. J. Neurosci. Methods 92:193–204.

49. Armao, D., M. Kornfeld, E.Y. Estrada, M. Grossetete, and G.A. Loscalzo. 2000. Tumor necrosis factor-alpha and interleukin-1beta mediate neutrophil infiltration of the injured brain. J. Neurosci. Methods 92:193–204.

50. Armao, D., M. Kornfeld, E.Y. Estrada, M. Grossetete, and G.A. Loscalzo. 2000. Tumor necrosis factor-alpha and interleukin-1beta mediate neutrophil infiltration of the injured brain. J. Neurosci. Methods 92:193–204.

51. Armao, D., M. Kornfeld, E.Y. Estrada, M. Grossetete, and G.A. Loscalzo. 2000. Tumor necrosis factor-alpha and interleukin-1beta mediate neutrophil infiltration of the injured brain. J. Neurosci. Methods 92:193–204.

52. Armao, D., M. Kornfeld, E.Y. Estrada, M. Grossetete, and G.A. Loscalzo. 2000. Tumor necrosis factor-alpha and interleukin-1beta mediate neutrophil infiltration of the injured brain. J. Neurosci. Methods 92:193–204.

53. Armao, D., M. Kornfeld, E.Y. Estrada, M. Grossetete, and G.A. Loscalzo. 2000. Tumor necrosis factor-alpha and interleukin-1beta mediate neutrophil infiltration of the injured brain. J. Neurosci. Methods 92:193–204.

54. Armao, D., M. Kornfeld, E.Y. Estrada, M. Grossetete, and G.A. Loscalzo. 2000. Tumor necrosis factor-alpha and interleukin-1beta mediate neutrophil infiltration of the injured brain. J. Neurosci. Methods 92:193–204.

55. Armao, D., M. Kornfeld, E.Y. Estrada, M. Grossetete, and G.A. Loscalzo. 2000. Tumor necrosis factor-alpha and interleukin-1beta mediate neutrophil infiltration of the injured brain. J. Neurosci. Methods 92:193–204.

56. Armao, D., M. Kornfeld, E.Y. Estrada, M. Grossetete, and G.A. Loscalzo. 2000. Tumor necrosis factor-alpha and interleukin-1beta mediate neutrophil infiltration of the injured brain. J. Neurosci. Methods 92:193–204.

57. Armao, D., M. Kornfeld, E.Y. Estrada, M. Grossetete, and G.A. Loscalzo. 2000. Tumor necrosis factor-alpha and interleukin-1beta mediate neutrophil infiltration of the injured brain. J. Neurosci. Methods 92:193–204.